A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase Chronic Myelogenous Leukemia
Subjects with a pathologic confirmation of the diagnosis of AML, ALL, or blast-phase CML ECOG Performance Status 0-2 Adequate organ function as defined in the protocol. Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
Hyperleukocytosis Acute Promyelocytic Leukemia (FAB-M3) subtype Uncontrolled Disseminated Intravascular Coagulation (DIC) Active central nervous system leukemia Concomitant radiation therapy, chemotherapy, or immunotherapy Women who are pregnant or lactating Neuropathy ≥ grade 2 (NCI CTCAE) at time of enrollment Chemotherapy (with the exception of hydroxyurea) or radiotherapy within two weeks or within six times the agent's half life Require ongoing therapy with either G- or GM-CSF, or long-acting versions of these molecules Use of any investigational agents within two weeks or within six times the agent's half life --Treatment with chronic immunosuppressants Other medical/psychiatric condition that may increase the risk associated with study participation as defined by the protocol.
